24.89
Indivior Plc Borsa (INDV) Ultime notizie
Indivior Q2 2025 presentation: SUBLOCADE growth drives raised guidance By Investing.com - Investing.com Australia
Earnings call transcript: Indivior’s Q2 2025 revenue rises, guidance boosted By Investing.com - Investing.com Canada
Using Python tools to backtest Indivior PLC strategiesSwing Trade & Long-Term Safe Investment Ideas - newser.com
Will Indivior PLC stock deliver long term returnsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Can Indivior PLC stock reach $100 price target2025 Price Momentum & Low Risk Entry Point Guides - newser.com
Substance Abuse Treatment Market to Witness Remarkable Growth With Indivior PLC, Pfizer, Inc. - openPR.com
News impact scoring models applied to Indivior PLCJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - newser.com
Chart based exit strategy for Indivior PLCEarnings Trend Report & Scalable Portfolio Growth Methods - newser.com
How Indivior PLC stock performs in rising dollar environment2025 EndofYear Setup & Weekly Market Pulse Alerts - newser.com
Indivior targets $1.5B peak revenue for Sublocade amid 2025 transition plans - MSN
Will Indivior PLC stock rally after Fed decisionsMarket Weekly Review & Weekly Momentum Picks - newser.com
Is Indivior PLC stock reversal real or fakeTrade Volume Report & Risk Controlled Stock Pick Alerts - newser.com
Will Indivior PLC benefit from macro trendsJuly 2025 Analyst Calls & Low Risk Investment Opportunities - newser.com
Strategies to average down on Indivior PLCJuly 2025 Review & Target Return Focused Picks - newser.com
Indivior PLC stock outlook for YEARTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Will Indivior PLC outperform the marketJuly 2025 Action & Expert Curated Trade Setups - newser.com
What indicators show strength in Indivior PLCTrade Analysis Report & Daily Volume Surge Signals - newser.com
U.S. Suboxone Market Set to See Booming Growth 2025-2032 Driven by Key Players like Indivior, Teva, and Alcami - openPR.com
Substance Abuse Treatment Market Size, Growth Analysis 2031 - openPR.com
What the charts say about Indivior PLC today2025 Risk Factors & Growth-Oriented Investment Plans - newser.com
Indivior Launches Action Agenda for Business Enhancement - MSN
What analysts say about Indivior PLC stockHigh Dividend Yield Stocks & Big Profit Small Budget - earlytimes.in
Automated trading signals detected on Indivior PLC2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Full technical analysis of Indivior PLC stockJuly 2025 Short Interest & Safe Capital Growth Trade Ideas - newser.com
Why Indivior PLC stock remains resilient2025 Retail Activity & Safe Investment Capital Preservation Plans - newser.com
Should you wait for a breakout in Indivior PLC2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Can momentum traders help lift Indivior PLCMarket Risk Report & Fast Moving Stock Watchlists - newser.com
Indivior PLC (INDV) Raises 2025 Guidance After Q2 Revenue Hits $302M - MSN
US AG stops misleading marketing of unauthorized opioid overdose drug by Indivior - The Pharma Letter
Indivior plans U.S. domicile shift from U.K. to enhance Nasdaq presence - Investing.com Nigeria
UK's Indivior to re-domicile to US after listing move - Global Banking | Finance | Review
Opvee, High-Profile Overdose Antidote No One Used, Discontinues Marketing - Filter
UK’s Indivior to re-domicile to US after listing move - 104.1 WIKY
Indivior proposes new corporate structure to achieve U.S. domiciliation - MarketScreener
Indivior (INDV) Plans U.S. Domicile Shift with New Parent Compan - GuruFocus
Indivior to pursue a change in domicile from the U.K. to the U.S - TipRanks
Indivior Announces Redomiciliation to U.S. from U.K. - TipRanks
Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation - WV News
Indivior PLC (INDV) Investor Outlook: Analyzing A 21% Upside In The Healthcare Sector - DirectorsTalk Interviews
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):